Table 2

Propensity score-matched comparison of vaccine in patients with cancer with and without PD-1B (N=134 pairs)

FactorPD-1BNo PD-1BP value
Matched baseline variables
Age, mean (SD)50.92 (10.45)50.94 (10.57)0.99
GenderMale34 (25.4%)35 (26.1%)0.89
Female100 (74.6%)99 (73.9%)
PathologyNSCLC46 (34.3%)45 (33.6%)0.97
GI60 (44.8%)62 (46.3%)
HN28 (20.9%)27 (20.1%)
ChemotherapyYes28 (20.9%)28 (20.9%)1
No106 (79.1%)106 (79.1%)
ECOG-PS092 (68.7%)97 (72.4%)0.43
142 (31.3%)37 (27.6%)
MetastasisYes10 (7.5%)9 (7.7%)0.81
No124 (92.5%)125 (93.3%)
Dose of vaccine157 (42.5%)54 (40.3%)0.71
277 (57.5%)80 (59.7%)
Comorbidity with rheumatic diseaseYes32 (23.9%)30 (22.4%)0.77
No102 (76.1%)104 (77.6%)
Follow-up variables
Serological status+90 (67.2%)95 (70.9%)0.51
44 (32.8%)39 (29.1%)
Antibody titers (U/mL), mean (SD)434.82 (507.34)415.79 (460.65)0.75
FatigueYes19 (14.2%)26 (19.4%)0.25
No115 (85.8%)108 (80.6%)
FeverYes12 (9.0%)9 (6.7%)0.50
No122 (91.0%)125 (93.3%)
LymphadenopathyYes15 (11.2%)15 (11.2%)1.00
No119 (88.8%)119 (88.8%)
NauseaYes15 (11.2%)15 (11.2%)1
No119 (88.8%)119 (88.8%)
HeadacheYes13 (9.7%)13 (9.7%)1
No121 (90.3%)121 (90.3%)
RashYes35 (26.1%)10 (7.5%)<0.01
No99 (73.9%)124 (92.5%)
ArthralgiaYes18 (13.4%)15 (11.2%)0.58
No116 (85.6%)119 (88.8%)
  • ECOG-PS, Eastern Cooperative Oncology Group-Performance Score; GI, gastrointestinal cancers; HN, head and neck cancers; NSCLC, Non-small cell lung cancer; PD-1B, formance Scor-1 blockers; SD, standard deviation.